Journal of Gastrointestinal Cancer

, Volume 45, Issue 3, pp 268–275

Phase II Trial of Adjuvant Oral Thalidomide Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Disease from Colorectal/Appendiceal Cancer

  • Perry Shen
  • Christopher R. Thomas
  • Joyce Fenstermaker
  • Mebea Aklilu
  • Thomas P. McCoy
  • Edward A. Levine
Original Research



This phase II single-institution trial of adjuvant thalidomide after cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with appendiceal and colorectal malignancies sought to detect an improvement in progression-free survival (PFS) from 7 to 12 months.


Eligible patients received CS, HIPEC, and baseline imaging, followed by pretreatment thalidomide counseling. All participants were then started on a 28-day regimen of thalidomide, 100 mg by mouth at bedtime, followed by 200 mg for 4 weeks, followed by 300 mg as the final maintenance dose, as tolerated.


Twenty-seven eligible patients (median age 52 years; 52 % appendiceal/48 % colorectal) were enrolled on this trial and included in the analysis, and 26 were evaluable for response. Eighteen patients demonstrated stable disease on adjuvant thalidomide, while eight showed evidence of progression. Approximately 30 % of the patients withdrew due to toxicity. Grade 3/4 toxicities included neurological disorders (16 %), nausea (12 %), vomiting (8 %), and thromboembolism (8 %). Median overall survival (OS) and PFS were 43.0 and 9.3 months, respectively, and median follow-up was 40.4 months. Multivariate modeling showed significant improvements in PFS and OS for appendiceal patients and those with R0 or R1 resections. On an intent-to-treat analysis, the PFS of the study group was 9 months.


Based on these findings, thalidomide cannot be recommended as adjuvant therapy after CS and HIPEC for gastrointestinal malignancies. Further research is needed to identify active agents in this population.


Peritoneal carcinomatosis Cytoreductive surgery Hyperthermic intraperitoneal chemotherapy Thalidomide 

Supplementary material

12029_2014_9578_MOESM1_ESM.pdf (21 kb)
ESM 1(PDF 20 kb)
12029_2014_9578_MOESM2_ESM.pdf (12 kb)
ESM 2(PDF 11 kb)
12029_2014_9578_MOESM3_ESM.pdf (7 kb)
ESM 3(PDF 6 kb)
12029_2014_9578_MOESM4_ESM.pdf (7 kb)
ESM 4(PDF 7 kb)


  1. 1.
    Dawson LE, Russell AH, Tong D, et al. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surg Oncol. 1983;22:95–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Chu DZ, Lang NP, Thompson C, et al. PSD in nongynecologic malignancy: a prospective study of prognostic factors. Cancer. 1989;63:3643–67.CrossRefGoogle Scholar
  3. 3.
    Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16(4 Suppl 6):83–97.PubMedGoogle Scholar
  4. 4.
    Sugarbaker PH, Landy D, Jaffe G, et al. Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with PSD from cystadenocarcinoma of the colon or appendix. Cancer. 1990;65:1495–501.PubMedCrossRefGoogle Scholar
  5. 5.
    Stewart 4th JH, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13(5):624–34.PubMedCrossRefGoogle Scholar
  6. 6.
    Shen P, Stewart 4th JH, Levine EA. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer with peritoneal surface disease. Curr Probl Cancer. 2009;33:154–67.PubMedCrossRefGoogle Scholar
  7. 7.
    Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333(26):1757–63.PubMedCrossRefGoogle Scholar
  8. 8.
    Vile R. Cancer therapy. Less blood means more sanguinity. Curr Biol. 1995;5(1):10–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Bikfalvi A. Significance of angiogenesis in tumour progression and metastasis. Eur J Cancer. 1995;31A(7/8):1101–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Or R, Feferman R, Shoshan S. Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp Hematol. 1998;26:217–21.PubMedGoogle Scholar
  11. 11.
    Kenyon B, Browne F, D’Amato R. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Stewart 4th JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol. 2005;12:765–77.PubMedCrossRefGoogle Scholar
  13. 13.
    Dindo D, Demartines N, Calvien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of PSD from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92.PubMedCrossRefGoogle Scholar
  15. 15.
    Sadeghi B, Arvieux C, Glehen O, et al. PSD from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.PubMedCrossRefGoogle Scholar
  16. 16.
    Verwaal VJ, Van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with PSD of colorectal cancer. J Clin Oncol. 2003;21:3737–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Abramson N, Stokes PK, Luke M, et al. Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide. J Clin Oncol. 2002;20:1147–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Chan JK, Manuel MR, Ciaravino G, et al. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. Gynecol Oncol. 2006;103:919–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Lago LD, Richter MF, Cancela AI, et al. Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Invest New Drugs. 2003;21:359–66.CrossRefGoogle Scholar
  20. 20.
    Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for the treatment of multiple myeloma: 10 years later. Blood. 2008;111:3968–77.PubMedCrossRefGoogle Scholar
  21. 21.
    Kaushal V, Kaushal GP, Melkaveri SN, et al. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost. 2004;2:327–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17:775–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Ronnett BM, Yan H, Sugarbaker PH, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous surface disease. Cancer. 2001;92(1):85–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for PSD from colorectal carcinoma. J Clin Oncol. 2006;24:4011–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Levine EA, Stewart 4th JH, Russell GB, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204:943–55.PubMedCrossRefGoogle Scholar
  26. 26.
    Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11:178–86.PubMedCrossRefGoogle Scholar
  27. 27.
    O’Neil BH, Goldberg RM. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist. 2008;13:1074–83.PubMedCrossRefGoogle Scholar
  28. 28.
    Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11–6.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Perry Shen
    • 1
  • Christopher R. Thomas
    • 2
  • Joyce Fenstermaker
    • 1
  • Mebea Aklilu
    • 3
  • Thomas P. McCoy
    • 4
  • Edward A. Levine
    • 1
  1. 1.Surgical Oncology ServiceWake Forest Baptist HealthWinston-SalemUSA
  2. 2.Piedmont Hematology and OncologyWinston-SalemUSA
  3. 3.Advocate Illinois Masonic Medical Center, Creticos Cancer CenterChicagoUSA
  4. 4.The University of North Carolina at Greensboro School of NursingGreensboroUSA

Personalised recommendations